DRAGARWQ
Dr. Agarwal'S Eye Hospital Limited
Each stock's 10,000-path forecast, rendered as light.
Dr. Agarwal'S Eye Hospital Limited (DRAGARWQ) Stock Analysis & Case Study
Is DRAGARWQ a good buy? The data-driven verdict.
Dr. Agarwal'S Eye Hospital Limited (DRAGARWQ) trades at ₹5,286,on the numbers it mixed signals, a Downstox Snapshot Score of 54/100.
On the numbers, Dr. Agarwal'S Eye Hospital Limited (DRAGARWQ) mixed signals, a Downstox Snapshot Score of 54/100, weighing premium at 33.5× earnings, ROE of 25.2%, a 57% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
DRAGARWQ fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How DRAGARWQ ranks against the 2,373 companies in our screener
- DRAGARWQ's market cap of 2,554 Cr ranks in the 54th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DRAGARWQ's book value of ₹717 ranks in the 94th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DRAGARWQ's promoter holding of 72.7% ranks in the 82nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DRAGARWQ's 3-year profit (PAT) growth of 24.0% ranks in the 62nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DRAGARWQ's 3-year revenue growth of 21.0% ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- DRAGARWQ's debt-to-equity ratio of 0.94x is lower than 16% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is DRAGARWQ overvalued? DRAGARWQ P/E vs peers
DRAGARWQ trades at 33.5× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
DRAGARWQ share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of DRAGARWQ history (32%/yr drift, 39%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| DRAGARWQ 2027 | ₹3,440 | ₹5,638 | ₹9,241 | +7% |
| DRAGARWQ 2028 | ₹3,030 | ₹6,053 | ₹12,089 | +15% |
| DRAGARWQ 2029 | ₹2,801 | ₹6,498 | ₹15,076 | +24% |
| DRAGARWQ 2030 | ₹2,644 | ₹6,976 | ₹18,401 | +33% |
| DRAGARWQ 2031 | ₹2,508 | ₹7,489 | ₹22,362 | +43% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability DRAGARWQ goes up, or doubles?
The bull case for DRAGARWQ
- DRAGARWQ's return on equity of 25.2% ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹15,076.
The bear case & risks
- DRAGARWQ's P/E of 33.5x is lower than 41% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹2,801.
DRAGARWQ volatility & expected range, how bumpy is the ride?
Over the last 9.8 years DRAGARWQ compounded at 32%/year with annualized volatility of 39%. That volatility implies a 1-year 80% range of ₹3,440-₹9,241, the honest backbone behind any single price target.
DRAGARWQ price forecast, the full 60-month probability fan
DRAGARWQ price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds DRAGARWQ hits common targets within the simulated horizon?
Full multi-horizon detail on the DRAGARWQ price target & forecast page.
DRAGARWQ Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. DRAGARWQ scores 6/8, mixed financial health.
DRAGARWQ MTF margin & leverage across 4 brokers
Margin Trading Facility lets you buy DRAGARWQ with part of the capital. Lower margin % = higher leverage. Rates compared across 4 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 50.00% | 2.0× |
| Pocketful | 50.00% | 2.0× |
| Share IndiaCHEAPEST | 30.86% | 3.2× |
Compare every broker on the DRAGARWQ MTF page.
About Dr. Agarwal'S Eye Hospital Limited: sector, index & market-cap context
Dr. Agarwal'S Eye Hospital Limited (DRAGARWQ) is a small-cap NSE-listed company, with a market capitalisation of ₹2,554 Cr. See more stocks on our screener.
How the DRAGARWQ Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Dr. Agarwal'S Eye Hospital Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
DRAGARWQ analysis, FAQs
Is Dr. Agarwal'S Eye Hospital Limited (DRAGARWQ) a good buy?
On the numbers, Dr. Agarwal'S Eye Hospital Limited (DRAGARWQ) mixed signals, a Downstox Snapshot Score of 54/100, weighing premium at 33.5× earnings, ROE of 25.2%, a 57% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is DRAGARWQ overvalued or undervalued?
DRAGARWQ trades at 33.5× earnings, premium versus the ~22× long-run Nifty average.
What is the DRAGARWQ share price target for 2031?
DRAGARWQ's probability-weighted 2031 median target is ₹7,489, with an 80% range of ₹2,508-₹22,362 (10,000-path Monte-Carlo).
What is the probability DRAGARWQ doubles in 5 years?
The modelled probability of DRAGARWQ reaching ₹10,503 (2×) within 5 years is 35%.
What is the bull case for DRAGARWQ?
DRAGARWQ's return on equity of 25.2% ranks in the 90th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in DRAGARWQ?
DRAGARWQ's P/E of 33.5x is lower than 41% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.